Form 4 for CALC CalciMedica, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001415889-24-001830 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-01-25 | 2024-01-23 | CALC | Sanderling Venture Partners VI LP | 10% | P - Purchase | $3.70 | +436.0K | 727.4K | +150% | +$1.61M |
| D | 2024-01-25 | 2024-01-23 | CALC | Sanderling Venture Partners VI LP | 10% | P - Purchase | $3.70 | +243.4K | 946.7K | +35% | +$900.4K |
| DM | 2024-01-25 | 2024-01-23 | CALC | Sanderling Venture Partners VI LP | 10% | P - Purchase | $0.13 | +243.4K | 121.7K | New | +$31.6K |
| DMI | 2024-01-25 | 2024-01-23 | CALC | Sanderling Venture Partners VI LP | 10% | P - Purchase | $0.13 | +436.0K | 97.2K | New | +$56.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | P | A | 28,744 | $3.70 | 30,292 | I By Sanderling Ventures Management VII | — | — | |
| 2 | Common | Common Stock | 2024-01-23 | P | A | 3,920 | $3.70 | 21,602 | I By Sanderling Ventures Management VI | — | — | |
| 3 | Common | Common Stock | 2024-01-23 | P | A | 13,184 | $3.70 | 27,609 | I By Sanderling Ventures VII Annex Fund, L.P. | — | — | |
| 4 | Common | Common Stock | 2024-01-23 | P | A | 51,032 | $3.70 | 114,260 | I By Sanderling Ventures VII (Canada), L.P. | — | — | |
| 5 | Common | Common Stock | 2024-01-23 | P | A | 194,472 | $3.70 | 435,148 | I By Sanderling Ventures VII, L.P. | — | — | |
| 6 | Common | Common Stock | 2024-01-23 | P | A | 243,356 | $3.70 | 946,744 | D | — | — | |
| 7 | Common | Common Stock | 2024-01-23 | P | A | 144,676 | $3.70 | 727,433 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | — | — | |
| 8 | Derivative | Warrant | 2024-01-23 | P | A | 121,678 | $0.13 | 121,678 | D | $7.15 · 2024-01-23 to 2026-12-31 | 121,678 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 9 | Derivative | Warrant | 2024-01-23 | P | A | 25,516 | $0.13 | 25,516 | I By Sanderling Ventures VII (Canada), L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 25,516 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 10 | Derivative | Warrant | 2024-01-23 | P | A | 121,678 | $0.13 | 121,678 | D | $5.36 · 2024-01-23 to 2024-12-31 | 121,678 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 11 | Derivative | Warrant | 2024-01-23 | P | A | 25,516 | $0.13 | 25,516 | I By Sanderling Ventures VII (Canada), L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 25,516 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 12 | Derivative | Warrant | 2024-01-23 | P | A | 72,338 | $0.13 | 72,338 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 72,338 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 13 | Derivative | Warrant | 2024-01-23 | P | A | 14,372 | $0.13 | 14,372 | I By Sanderling Ventures Management VII | $7.15 · 2024-01-23 to 2026-12-31 | 14,372 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 14 | Derivative | Warrant | 2024-01-23 | P | A | 14,372 | $0.13 | 14,372 | I By Sanderling Ventures Management VII | $5.36 · 2024-01-23 to 2024-12-31 | 14,372 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 15 | Derivative | Warrant | 2024-01-23 | P | A | 1,960 | $0.13 | 1,960 | I By Sanderling Ventures Management VI | $7.15 · 2024-01-23 to 2026-12-31 | 1,960 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 16 | Derivative | Warrant | 2024-01-23 | P | A | 1,960 | $0.13 | 1,960 | I By Sanderling Ventures Management VI | $5.36 · 2024-01-23 to 2024-12-31 | 1,960 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 17 | Derivative | Warrant | 2024-01-23 | P | A | 6,592 | $0.13 | 6,592 | I By Sanderling Ventures VII Annex Fund, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 6,592 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 18 | Derivative | Warrant | 2024-01-23 | P | A | 6,592 | $0.13 | 6,592 | I By Sanderling Ventures VII Annex Fund, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 6,592 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 19 | Derivative | Warrant | 2024-01-23 | P | A | 72,338 | $0.13 | 72,338 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 72,338 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 20 | Derivative | Warrant | 2024-01-23 | P | A | 97,236 | $0.13 | 97,236 | I By Sanderling Ventures VII, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 97,236 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 21 | Derivative | Warrant | 2024-01-23 | P | A | 97,236 | $0.13 | 97,236 | I By Sanderling Ventures VII, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 97,236 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |